Key result
Review outlines nucleic acid-based vaccine design strategies targeting T. cruzi surface antigens for Chagas disease.
Why the study?
Current treatments for Chagas disease have significant side effects, require long durations, and do not improve chronic cardiomyopathy, motivating the development of therapeutic vaccines.
Population
People infected with or at risk for Trypanosoma cruzi in endemic and non-endemic areas
Comparison
Nucleic acid-based vaccines targeting T. cruzi surface antigens
Design
Review article
Authors
Loading...
Chagas nucleic acid vaccines remain investigational; this review leaves open their role in preventing cardiomyopathy.
This review highlights the potential of nucleic acid-based vaccines targeting T. cruzi surface antigens to prevent or treat Chagas disease and its chronic complications such as cardiomyopathy.
Maldonado et al. (2022) conducted a review in Chagas disease. Nucleic acid-based vaccines was evaluated. This review discusses T. cruzi surface antigens and nucleic acid-based vaccine design strategies, presenting an example of a chimeric trivalent vaccine for Chagas disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: